Skip to main content

Table 1 Characteristics of included primary studies

From: Routes of administration, reasons for use, and approved indications of medical cannabis in oncology: a scoping review

Design (n = 62) N (%)
Survey 23 (37.1)
Randomized controlled trial 13 (21.0)
Observational study 9 (14.5)
Pilot study 5 (8.1)
Qualitative study 3 (4.8)
Phenomenology 2 (3.2)
Case report 2 (3.2)
Protocol for a randomized controlled trial 2 (3.2)
Pre experimental study 1 (1.6)
Quality improvement study 1 (1.6)
Descriptive study 1 (1.6)
Countries (n = 62) N (%)
United States 27 (43.5)
Canada 9 (14.5)
Australia 9 (14.5)
Israel 8 (12.9)
United Kingdom 3 (4.8)
Denmark 1 (1.6)
France 1 (1.6)
Germany 1 (1.6)
Italy 1 (1.6)
Mexico 1 (1.6)
Spain 1 (1.6)
Type of cancer (n = 18,684) N (%)
Gastrointestinal (including colorectal, intestinal, liver, oesophageal, oral, pancreas, rectal, stomach) 2288 (12.2)
Breast 2236 (12.0)
Genitourinary (including bladder, cervical, ovarian, peritoneal, prostate, renal, testicular, vaginal) 1835 (9.8)
Hematologic (including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome) 1655 (8.9)
Lung 1615 (8.6)
Skin (including melanoma) 292 (1.6)
Neurological (including brain, central nervous system, neuroendocrine) 291 (1.6)
Head and neck 287 (1.5)
Sarcoma 160 (0.9)
Hepatobiliary 36 (0.2)
Kidney 16 (0.1)
Musculoskeletal 13 (0.1)
Thyroid 11 (0.1)
Not reported 7,949 (42.5)
Sex of participants (n = 20,069) *include protocols N (%)
Female 9857 (49.1)
Male 9627 (48.0)
Not reported 585 (2.9)